News
TCBP
0.4598
+1.50%
0.0068
Weekly Report: what happened at TCBP last week (0106-0110)?
Weekly Report · 2d ago
TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance
TipRanks · 6d ago
Weekly Report: what happened at TCBP last week (1230-0103)?
Weekly Report · 01/06 10:33
Upcoming Stock Splits This Week (January 6 to January 10) – Stay Invested
TipRanks · 01/06 07:14
TC Biopharm Announces Special Stock Dividend and Temporary Trading Halt
TipRanks · 12/31/2024 19:27
TC Biopharm advances negotiations with acquisition candidates
TipRanks · 12/31/2024 15:20
TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility
TipRanks · 12/30/2024 19:47
TC Biopharm shareholders approve 25% stock dividend
TipRanks · 12/30/2024 15:35
Weekly Report: what happened at TCBP last week (1223-1227)?
Weekly Report · 12/30/2024 10:29
Weekly Report: what happened at TCBP last week (1216-1220)?
Weekly Report · 12/23/2024 10:33
TC Biopharm advances ACHIEVE Phase 2b clinical trial
TipRanks · 12/20/2024 13:35
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/18/2024 21:06
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
Benzinga · 12/18/2024 13:00
TC BioPharm Advances Strategic Financial Initiative with New ADS Offering
TipRanks · 12/17/2024 13:57
TC BioPharm Announces Key Shareholder Meeting
TipRanks · 12/16/2024 21:27
Weekly Report: what happened at TCBP last week (1209-1213)?
Weekly Report · 12/16/2024 10:34
TC Biopharm Partners With CareDx For ACHIEVE Phase II Study
NASDAQ · 12/11/2024 14:06
TC Biopharm announces partnership with CareDx
TipRanks · 12/11/2024 12:10
Weekly Report: what happened at TCBP last week (1202-1206)?
Weekly Report · 12/09/2024 10:33
TC BioPharm Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/06/2024 11:26
More
Webull provides a variety of real-time TCBP stock news. You can receive the latest news about TC BioPharm (Holdings) Ltd through multiple platforms. This information may help you make smarter investment decisions.
About TCBP
TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies (GD-Ts) for the treatment of cancer with human efficacy data in acute myeloid leukemia. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. It is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.